Effect of compound rhodiola cretinii on VEGF expression in retina of rats with diabetes mellitus

Chinese Ophthalmic Research

Volumn 28, Issue 6, 2010, Pages 513-517

  Zhao, Hong Shu ^a   Wei, Wen Bin ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chinese herbs; Compound rhodiola sachalinensis; Diabetic retinopathy; Immunohistochemistry; RT PCR; VEGF

Indexed keywords

RHODIOLA EXTRACT; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG ACTIVITY; GLUCOSE BLOOD LEVEL; IMMUNOCHEMISTRY; NONHUMAN; PHOTORECEPTOR; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; RETINA; RETINA BIPOLAR GANGLION CELL; RETINA GANGLION CELL; RHODIOLA; RHODIOLA CRETINII; STREPTOZOCIN DIABETES;

EID: 77954197424     PISSN: 10030808     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1003-0808.2010.06.009     Document Type: Article

References (20)

1. Duh E, Aiello LP. Vascular endothelial growth factor and diabetes : the agonist versus antagonist paradox[J]. Diabetes, 1999,48(10):1899-1906. (Pubitemid 29458350)
2. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders[J]. N Engl J Med, 1994,331(22):1480-1487.
3. Aiello LP. Vascular endothelial growth factor and the eye : biochemical mechanisms of action and implications for novel therapies [J]. Ophthalmic Res, 1997,29(5):354-362.
4. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization [J]. Invest Ophthalmol Vis Sci, 1998,39(1):18-22.
5. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate[J]. Arch Ophthalmol, 1996, 114(1):66-71.
6. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor( VEGF) using soluble VEGF-receptor chimeric proteins[ J]. Proc Natl Acad Sci USA, 1995,92(23):10457-10461.
7. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment[J]. Arch Ophthalmol, 2002,120(3): 338-346.
8. Chan CK, Pham LN, Zhou J, et al. Differential expression of proandantiangiogenic factors in mousestrain-dependent hypoxia-inducedretinal neovascularization[J]. Lab Invest, 2005,85(6):721-733.
9. Degenhardt TP, Thorpe SR, Baynes JW. Chemical modification of proteins by methylglyoxal [J]. Cell Mol Biol ( Noisy-le-grand ), 1998, 44(7):1139-1145.
10. Aiello LP, Avery RL, Arrig PG, et al. Vascular endothelial growth factor in ocular fluid of patients with retinopathy and other retinal disorders [J]. N Engl J Med, 1994,331(22):1480-1487.
11. Vassara H, Fuh H, Makita Z, et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals : a model for diabetic and aging complications [J]. Proc Natl Acad Sci USA, 1992,89(24):12043-12047.
12. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration[J]. N Engl J Med, 2004, 351(27):2805-2816.
13. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration [J]. Ophthalmology, 2005,112(6):1048-1053.
14. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP ( R1R2 ) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier[J]. J Cell Physiol, 2003,195:241-248.
15. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization[J]. Am J Pathol, 2000,156(2):697-707. (Pubitemid 30643824)
16. Aiello LP. Angiogenic pathways in diabetic retinopathy [J]. N Engl J Med, 2005,353(8):839-841.
17. Hsiao G, Chen YC, Lin JH, et al. Inhibitory mechanisms of tetramethylpyrazine in middle cerebral artery occlusion ( MCAO ) - induced focal cerebral ischemia in rats [J]. Planta Med, 2006,2(5): 411-417.
18. Kao TK, Ou YC, Kuo JS, et al. Neuroprotection by tetramethylpyrazine against ischemic brain injury in rats[J]. Neurochem Int, 2006,48(3): 166-176.